Treatment with high-dose vitamin D reduced disease activity in people with clinically isolated syndrome in a Phase 3 trial.

Researchers from CHU Nîmes, Université Montpellier, and multiple MS centers in France have found that oral cholecalciferol in doses of 100,000 IU every two weeks significantly reduced disease activity ...

Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Paris: A French study has revealed that taking vitamin D3 (cholecalciferol) orally at a dose of 100,000 international units ...

Tom Nolan reviews this week’s research There are so many studies published about vitamin D—about a dozen each day—it’s hard to keep up. One that stands out is a double-blind randomised controlled ...

Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and ...

Norges Bank acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional ...

Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other ...

High-dose oral cholecalciferol (vitamin D3) supplementation significantly reduced disease activity in patients with clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS) in the ...